Stryker Co. (NYSE:SYK) CFO Glenn S. Boehnlein sold 750 shares of the stock in a transaction dated Monday, April 16th. The stock was sold at an average price of $160.00, for a total transaction of $120,000.00. Following the sale, the chief financial officer now owns 3,535 shares in the company, valued at approximately $565,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Stryker stock opened at $163.55 on Friday. The company has a quick ratio of 1.59, a current ratio of 2.29 and a debt-to-equity ratio of 0.66. The company has a market capitalization of $61,310.16, a PE ratio of 25.20, a P/E/G ratio of 2.35 and a beta of 0.70. Stryker Co. has a 12-month low of $131.20 and a 12-month high of $170.00.
Stryker (NYSE:SYK) last posted its quarterly earnings data on Tuesday, January 30th. The medical technology company reported $1.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.95 by $0.01. The business had revenue of $3.47 billion during the quarter, compared to analysts’ expectations of $3.42 billion. Stryker had a net margin of 8.20% and a return on equity of 24.56%. The business’s revenue was up 9.9% on a year-over-year basis. During the same period last year, the firm posted $1.78 earnings per share. sell-side analysts anticipate that Stryker Co. will post 7.12 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Monday, April 30th. Stockholders of record on Thursday, March 29th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 1.15%. The ex-dividend date is Wednesday, March 28th. Stryker’s dividend payout ratio (DPR) is presently 28.97%.
Several equities research analysts have commented on the stock. Zacks Investment Research upgraded shares of Stryker from a “sell” rating to a “hold” rating and set a $177.00 price target on the stock in a research note on Thursday, April 12th. Evercore ISI assumed coverage on shares of Stryker in a research note on Monday, April 2nd. They issued an “in-line” rating and a $165.00 price target on the stock. Raymond James assumed coverage on shares of Stryker in a research note on Thursday, March 15th. They issued an “outperform” rating and a $183.00 price target on the stock. ValuEngine upgraded shares of Stryker from a “hold” rating to a “buy” rating in a research note on Thursday, March 1st. Finally, Citigroup upgraded shares of Stryker from a “sell” rating to a “neutral” rating and raised their price target for the company from $165.77 to $166.00 in a research note on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, ten have assigned a hold rating and sixteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $165.27.
Several institutional investors have recently bought and sold shares of SYK. Buckingham Capital Management Inc. boosted its holdings in Stryker by 9.4% during the third quarter. Buckingham Capital Management Inc. now owns 10,521 shares of the medical technology company’s stock worth $1,494,000 after buying an additional 905 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in Stryker by 0.8% during the third quarter. Dimensional Fund Advisors LP now owns 636,017 shares of the medical technology company’s stock worth $90,320,000 after buying an additional 5,267 shares in the last quarter. Steward Partners Investment Advisory LLC bought a new stake in Stryker during the third quarter worth approximately $538,000. Atlantic Trust Group LLC boosted its holdings in Stryker by 1.2% during the third quarter. Atlantic Trust Group LLC now owns 1,186,100 shares of the medical technology company’s stock worth $168,449,000 after buying an additional 13,657 shares in the last quarter. Finally, Oak Point Wealth Management bought a new stake in Stryker during the fourth quarter worth approximately $145,000. Institutional investors and hedge funds own 75.66% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Stryker Co. (SYK) CFO Sells $120,000.00 in Stock” was first reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and reposted in violation of US & international trademark & copyright laws. The correct version of this piece of content can be viewed at https://ledgergazette.com/2018/04/20/stryker-co-syk-cfo-sells-120000-00-in-stock.html.
Stryker Company Profile
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.